| CD4 Only | VL Only | CD4 and VL | No CD4 or VL | Totala | ≥1 CD4 or VLc | ≥1 CD4 or VL Chi-Square p-Value | |
|---|---|---|---|---|---|---|---|
| No. (%) | No. (%) | No. (%) | No. (%) | No. (%)b | No. (%) | ||
| Sex | |||||||
| Male | 149 (6.8) | 112 (5.1) | 1,454 (66.1) | 484 (22.0) | 2,199 (71.7) | 1,715 (78.0) | Reference |
| Female | 53 (6.1) | 53 (6.2) | 586 (67.6) | 174 (20.1) | 866 (28.3) | 692 (79.9) | 0.25 |
| Race/Ethnicity | |||||||
| Black/African American | 117 (8.0) | 60 (4.1) | 900 (61.5) | 386 (26.4) | 1,463 (47.7) | 1,077 (73.6) | < 0.001 |
| Hispanic/Latino | 18 (5.1) | 16 (4.5) | 267 (73.6) | 61 (16.9) | 362 (11.8) | 301 (83.1) | 0.99 |
| White | 51 (4.8) | 75 (7.1) | 755 (71.3) | 179 (16.9) | 1,059 (34.6) | 880 (82.1) | Reference |
| Multiple races/Other raced | 16 (8.8) | 14 (7.7) | 118 (65.4) | 33 (18.1) | 181 (5.9) | 148 (81.9) | 0.69 |
| Age | |||||||
| 13-29 | 49 (5.3) | 45 (4.8) | 575 (62.1) | 257 (27.7) | 926 (30.2) | 669 (72.3) | 0.03 |
| 30-39 | 56 (6.3) | 50 (5.6) | 579 (64.9) | 208 (23.3) | 893 (29.1) | 685 (76.7) | Reference |
| 40-49 | 62 (7.6) | 44 (5.4) | 571 (70.3) | 136 (16.8) | 813 (26.5) | 677 (83.2) | < 0.001 |
| ≥50 | 34 (7.9) | 27 (6.2) | 315 (72.5) | 58 (13.4) | 434 (14.2) | 376 (86.6) | < 0.001 |
| Transmission Category | |||||||
| Male Adult or Adolescent | |||||||
| Male-to-male sexual contact | 86 (5.5) | 79 (5.0) | 1058 (67.5) | 344 (21.9) | 1,567 (71.3) | 1,223 (78.1) | Reference |
| Injection drug use | 23 (11.8) | 8 (4.4) | 116 (60.7) | 44 (23.1) | 191 (8.7) | 147 (76.9) | 0.71 |
| Male-to-male sexual contact and injection drug use | 17 (10.8) | 5 (3.4) | 103 (66.3) | 30 (19.5) | 156 (7.1) | 126 (80.5) | 0.49 |
| Heterosexual contacte | 21 (7.6) | 18 (6.4) | 171 (62.1) | 66 (24.0) | 275 (12.5) | 209 (76.0) | 0.45 |
| Other | 2 (21.6) | 1 (14.7) | 6 (62.6) | 0 | 10 (0.4) | 10 (100.0) | f |
| Female Adult or Adolescent | |||||||
| Injection drug use | 12 (7.2) | 14 (8.3) | 118 (69.1) | 26 (15.4) | 171 (19.8) | 145 (84.6) | 0.07 |
| Heterosexual contact | 39 (5.8) | 39 (5.7) | 458 (67.0) | 148 (22.4) | 684 (79.0) | 536 (77.6) | Reference |
| Other | 1 (13.5) | 0 | 9 (82.6) | 0 | 11 (1.2) | 11 (100.0) | f |
| Project Area | |||||||
| Colorado | 24 (5.3) | 16 (3.6) | 338 (76.7) | 63 (14.3) | 440 (14.4) | 377 (85.7) | < 0.001 |
| Indiana | 28 (5.9) | 19 (4.1) | 307 (65.5) | 114 (24.4) | 468 (15.3) | 354 (75.6) | 0.61 |
| Louisiana | 89 (10.0) | 30 (3.3) | 568 (63.5) | 208 (23.2) | 895 (29.2) | 687 (76.8) | Reference |
| Michigan | 41 (7.6) | 17 (3.2) | 327 (60.6) | 154 (28.6) | 540 (17.6) | 386 (71.4) | 0.02 |
| New York | 20 (2.7) | 83 (11.5) | 500 (69.3) | 119 (16.5) | 722 (23.5) | 603 (83.5) | < 0.001 |
| Facility of Diagnosis | |||||||
| Private physician/HMO | 20 (4.2) | 30 (6.3) | 346 (73.1) | 78 (16.5) | 474 (15.5) | 396 (83.5) | 0.08 |
| Emergency room/Inpatient clinic | 87 (13.3) | 27 (4.2) | 457 (69.7) | 84 (12.9) | 656 (21.4) | 571 (87.1) | Reference |
| Adult HIV clinic | 10 (8.0) | 6 (5.0) | 104 (79.8) | 9 (7.2) | 130 (4.2) | 120 (93.0) | 0.008 |
| HIV counseling and testing site | 18 (5.2) | 13 (3.7) | 151 (44.0) | 161 (47.1) | 342 (11.2) | 181 (52.9) | <0.001 |
| STD clinic | 14 (11.4) | 2 (1.8) | 54 (45.1) | 50 (41.7) | 119 (3.9) | 69 (58.3) | < 0.001 |
| Correctional facility | 4 (4.1) | 4 (4.2) | 66 (65.0) | 27 (26.6) | 102 (3.3) | 75 (73.4) | 0.01 |
| Other clinic | 17 (4.0) | 20 (4.9) | 230 (55.1) | 150 (36.0) | 417 (13.6) | 267 (63.9) | <0.001 |
| Unknown | 32 (3.9) | 62 (7.6) | 633 (76.7) | 98 (11.9) | 825 (26.9) | 727 (88.1) | 0.02 |
| Total | 202 (6.6) | 165 (5.4) | 2,040 (66.6) | 659 (21.5) | 3,065 | 2,406 (78.5) | |